What is Metavention?
Metavention is a specialized medical technology firm dedicated to addressing the global burden of hypertension through innovative renal denervation procedures. The company's proprietary iRF Denervation System utilizes targeted radio frequency energy to disrupt overactive sympathetic nerves, a mechanism that has shown promise in lowering blood pressure and mitigating associated metabolic complications. By focusing on high-precision, minimally invasive interventions, Metavention occupies a critical niche at the intersection of interventional cardiology and metabolic health. Their commitment to rigorous clinical validation and patient-centric outcomes positions them as a high-authority player in the development of next-generation therapeutic devices designed to improve long-term patient prognosis.
How much funding has Metavention raised?
Metavention has raised a total of $42M across 2 funding rounds:
Series B
$12M
Series C
$30M
Series B (2014): $12M, investors not publicly disclosed
Series C (2017): $30M led by New Enterprise Associates, Versant Ventures, Sanderling Ventures, and Horowitz Group
Key Investors in Metavention
New Enterprise Associates
A prominent venture capital firm established in 1977 that provides strategic support and capital to entrepreneurs building transformative businesses across various sectors.
Versant Ventures
A global healthcare-focused investment firm with over $5.5 billion under management, specializing in building innovative biotechnology and medical device companies.
Sanderling Ventures
A pioneering biomedical investment firm founded in 1979 that focuses on early-stage financing and active management of companies within the therapeutics and medical device sectors.
What's next for Metavention?
With the successful closure of this major enterprise-level funding, Metavention is poised to transition from clinical validation to broader market preparation. The strategic roadmap likely involves scaling the deployment of the iRF Denervation System across international clinical sites and deepening the data set required for regulatory approval. As the company continues to refine its therapeutic platform, the focus will shift toward establishing long-term efficacy benchmarks and securing reimbursement pathways. This capital injection provides the necessary runway to navigate the complex regulatory landscape of the medical device industry, ensuring that their life-changing therapies reach healthcare providers and patients with high-unmet needs in the hypertension management space.
See full Metavention company page
